"I’m the one that has to live in my body, I’m doing what I need to get my life back, and that’s all that matters." ...
FDA has approved Lipfendra, developed by American pharmaceutical company Merck, for adults with high LDL cholesterol. It ...
Max Scherzer's 2026 season has been a rollercoaster, and now the Toronto Blue Jays veteran has dealt with a setback.
The FDA has approved a first-of-its-kind pill that can lower "bad" LDL cholesterol with a daily pill instead of a shot.
High cholesterol is one of the major risk factors for heart disease and stroke. While statins have been the most common ...
The USFDA has approved Lipfendra, the first oral PCSK9 inhibitor, for lowering LDL cholesterol. The once-daily pill could improve long-term adherence, though Indian access will depend on approval and ...
The clinical trials reviewed by the FDA found that adding Lipfendra to statin therapy reduced LDL cholesterol by approximately 56% to 60%.
A significant breakthrough in heart disease prevention arrived on July 16, 2026, with the FDA approval of Lipfendra ...
Pittsburgh doctors on Thursday hailed government approval of a highly effective anti-cholesterol pill that had previously ...
The U.S. Food and Drug Administration has approved Merck's Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor ...
For years, people with very high cholesterol who needed more than statins often had one major hurdle to overcome: injections.
Merck & Co. won US regulatory approval of a pill that rivals powerful injections for cutting dangerous cholesterol levels, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results